[go: up one dir, main page]

TNSN07393A1 - Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques - Google Patents

Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques

Info

Publication number
TNSN07393A1
TNSN07393A1 TNP2007000393A TNSN07393A TNSN07393A1 TN SN07393 A1 TNSN07393 A1 TN SN07393A1 TN P2007000393 A TNP2007000393 A TN P2007000393A TN SN07393 A TNSN07393 A TN SN07393A TN SN07393 A1 TNSN07393 A1 TN SN07393A1
Authority
TN
Tunisia
Prior art keywords
therapeutic applications
receptor ligands
novel histamine
novel
histamine
Prior art date
Application number
TNP2007000393A
Other languages
English (en)
Inventor
Isabelle Bertrand
Marc Capet
Jeanne-Marie Lecomte
Nicolas Levoin
Xavier Ligneau
Olivia Poupardin-Olivier
Philippe Robert
Jean-Charles Chwartz
Olivier Labeeuw
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05290950A external-priority patent/EP1717234A1/fr
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of TNSN07393A1 publication Critical patent/TNSN07393A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

La présente invention se rapporte à de nouveaux composés représentés par la formule (I), à leur procédé de préparation et à leur utilisation thérapeutique.
TNP2007000393A 2005-04-29 2007-10-24 Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques TNSN07393A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05290950A EP1717234A1 (fr) 2005-04-29 2005-04-29 Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
EP05291793A EP1717235A3 (fr) 2005-04-29 2005-08-26 Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
PCT/IB2006/000991 WO2006117609A2 (fr) 2005-04-29 2006-04-25 Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques

Publications (1)

Publication Number Publication Date
TNSN07393A1 true TNSN07393A1 (fr) 2009-03-17

Family

ID=37024927

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000393A TNSN07393A1 (fr) 2005-04-29 2007-10-24 Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques

Country Status (22)

Country Link
US (1) US8076329B2 (fr)
EP (2) EP1717235A3 (fr)
JP (1) JP5693814B2 (fr)
KR (1) KR101291575B1 (fr)
CN (1) CN101258138B (fr)
AU (1) AU2006242950B2 (fr)
BR (1) BRPI0612957B8 (fr)
CA (1) CA2606262C (fr)
DK (1) DK1874746T3 (fr)
EA (1) EA019594B1 (fr)
ES (1) ES2563065T3 (fr)
HU (1) HUE026549T2 (fr)
MA (1) MA29399B1 (fr)
MX (1) MX2007013384A (fr)
NO (1) NO340728B1 (fr)
NZ (1) NZ562873A (fr)
PL (1) PL1874746T3 (fr)
PT (1) PT1874746E (fr)
SG (1) SG162732A1 (fr)
SI (1) SI1874746T1 (fr)
TN (1) TNSN07393A1 (fr)
WO (1) WO2006117609A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653062A1 (fr) * 2006-05-23 2007-11-29 Transtech Pharma, Inc. Nouveaux medicaments
JP5335675B2 (ja) 2006-07-25 2013-11-06 セファロン、インク． ピリジジノン誘導体
US8115005B2 (en) * 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
WO2009097306A1 (fr) * 2008-01-30 2009-08-06 Cephalon, Inc. Dérivés de pyridazine substitués à activité antagoniste des récepteurs h3 de l'histamine
ES2390004T3 (es) 2008-01-30 2012-11-05 Cephalon, Inc. Derivados sustituidos de piperidina espirocíclica como ligandos del receptor de la histamina 3(H3)
KR101719550B1 (ko) 2008-07-02 2017-03-24 브리티쉬 콜롬비아 캔써 에이전시 브랜치 디글리시드 에테르 유도체 치료법 및 이의 사용 방법
CA2786319C (fr) 2010-01-06 2019-03-12 British Columbia Cancer Agency Branch Derives du bisphenol et leur utilisation en tant que modulateurs de l'activite du recepteur des androgenes
WO2011082488A1 (fr) * 2010-01-06 2011-07-14 British Columbia Cancer Agency Branch Agents thérapeutiques à base de dérivés du bisphénol et méthodes pour leur utilisation
TW201206939A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
CA2858342A1 (fr) 2011-12-08 2013-06-13 Taisho Pharmaceutical Co., Ltd. Derive de phenylpyrrole
WO2013100054A1 (fr) * 2011-12-27 2013-07-04 大正製薬株式会社 Dérivé de phényltriazole
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
KR101717872B1 (ko) * 2013-03-12 2017-03-17 (주)바이오팜솔루션즈 소아 간질 및 간질-관련 증후군의 예방 또는 치료용 페닐카바메이트 화합물
EP2994451A4 (fr) 2013-05-10 2016-10-05 British Columbia Cancer Agency Dérivés d'ester de modulateurs des récepteurs des androgènes et leurs procédés d'utilisation
KR20160054523A (ko) 2013-09-09 2016-05-16 브리티쉬 콜롬비아 캔써 에이전시 브랜치 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법
AU2016206412B2 (en) 2015-01-13 2020-10-08 British Columbia Cancer Agency Branch Heterocyclic compounds for cancer imaging and treatment and methods for their use
WO2016141458A1 (fr) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Dérivés d'éther de bisphénol et leurs procédés d'utilisation
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US10144706B2 (en) * 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3378858A1 (fr) 2017-03-21 2018-09-26 Bioprojet Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
EP3378477A1 (fr) * 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
WO2019226991A1 (fr) 2018-05-25 2019-11-28 Essa Pharma, Inc. Modulateurs du récepteur des androgènes et leurs procédés d'utilisation
EA202092979A1 (ru) * 2018-05-31 2021-03-12 Сувен Лайф Сайенсиз Лимитед Способ лечения обратным агонистом гистаминового рецептора 3 типа
ES2840253T3 (es) 2018-07-27 2021-07-06 Bioprojet Soc Civ Combinaciones novedosas de un antagonista de H3 y un inhibidor de la recaptación de noradrenalina y usos terapéuticos de los mismos
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
WO2020198712A1 (fr) 2019-03-28 2020-10-01 Essa Pharma, Inc. Compositions et combinaisons pharmaceutiques comprenant des inhibiteurs du récepteur des androgènes et utilisations de celles-ci
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914529A (en) * 1957-09-05 1959-11-24 Wm S Merrell Co Mono aminoethers of triphenyl ethylenes
BE788032A (fr) * 1971-08-25 1973-02-26 Hoechst Ag Isoindolines substituees leur procede de preparation et leurs applications
HU186655B (en) * 1982-12-28 1985-09-30 Richter Gedeon Vegyeszet Process for producing new piperidine derivatives, acid additional salts and quaternary salts and pharmaceutical compositions containing them
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
US4810713A (en) * 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
DE69009785T2 (de) * 1989-02-10 1994-11-03 Otsuka Pharma Co Ltd Carbostyrilderivate.
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
DE69222757T2 (de) 1991-02-27 1998-02-12 Seed Capital Investments Imidazol-derivate mit antagonistischer aktivität auf den histamin-h3-receptor
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
MY110108A (en) 1991-12-18 1998-01-27 Schering Corp Imidazolyl or imidazolylalkyl substituted with a four or five membered nitrigen containing heterocyclic ring
CA2126086C (fr) 1991-12-18 2000-03-28 Neng-Yang Shih Imidazoylalkyle substitue par un compose heterocyclique azote a six cycles
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
US5486526A (en) 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
WO1994017058A1 (fr) 1993-01-25 1994-08-04 The Green Cross Corporation Compose d'imidazole
WO1995006037A1 (fr) 1993-08-27 1995-03-02 Vrije Universiteit Nouveaux derives d'imidazoles a activite agoniste ou antagoniste du recepteur h3 a l'histamine
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
US6506876B1 (en) * 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
ES2170859T3 (es) 1995-05-30 2002-08-16 Gliatech Inc Derivados de imidazol 1h-4(5)-sustituidos.
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
EP0841923B1 (fr) 1995-06-07 2002-09-18 Gliatech, Inc. Derives d'imidazole a substitution 1h-4(5)
ATE242219T1 (de) 1996-02-09 2003-06-15 Black James Foundation Histamin h 3 rezeptorliganden
ATE282590T1 (de) * 1998-05-15 2004-12-15 Astrazeneca Ab Benzamid-derivate zur behandlung cytokin- vermittelter krankheiten
EP0982300A3 (fr) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
EE200200134A (et) 1999-09-14 2003-04-15 Aventis Pharmaceuticals Inc. D4 retseptori antagonistidena toimivad bensisoksasolüül-, püridoisoksasolüül- ja benstienüülfenoksüderivaadid
PT1268479E (pt) * 2000-03-31 2004-06-30 Ortho Mcneil Pharm Inc Derivados de indolizina fenil-substituidos e sua utilizacao como ligandos h3 de histamina
ATE430730T1 (de) 2000-03-31 2009-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
EP1268478B1 (fr) * 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Imidazopyridines phenyle-substituees
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
KR100819381B1 (ko) * 2000-08-08 2008-04-04 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시알킬아민
EP1379493A2 (fr) * 2001-03-23 2004-01-14 Eli Lilly and Company Composes d'aryl alkylamines non imidazole comme antagonistes des recepteurs h3 de l'histamine, preparation et applications therapeutiques
MXPA04006777A (es) * 2002-01-11 2004-11-10 Abbott Lab Ligandos de receptor de histamina-3 para condiciones diabeticas.
CA2484233A1 (fr) * 2002-05-13 2003-11-27 Eli Lilly And Company Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete
JP3949550B2 (ja) * 2002-09-11 2007-07-25 株式会社リコー 電子写真感光体、及び画像形成方法、画像形成装置、画像形成装置用プロセスカートリッジ
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
GB0224557D0 (en) * 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
JP2004262890A (ja) * 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
PT1660491E (pt) * 2003-07-28 2008-10-10 Janssen Pharmaceutica Nv Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
PL195384B1 (pl) * 2003-09-16 2007-09-28 Univ Adama Mickiewicza Nowe związki N-[(E)-4-stilbenylooksyalkilo] piperydyny oraz sposób ich otrzymywania
US20080242681A1 (en) * 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
AU2005212092B2 (en) * 2004-02-13 2011-01-20 Msd K.K. Fused-ring 4-oxopyrimidine derivative
US7645756B2 (en) * 2004-02-18 2010-01-12 Banyu Pharmaceutical Co. Ltd. Nitrogenous fused heteroaromatic ring derivative
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA84749C2 (ru) * 2004-04-07 2008-11-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
DK1773345T3 (en) 2004-06-30 2014-03-24 Athersys Inc NON-imidazol-tertiary amines AS HISTAMINE-3 receptor inhibitors in treating cognitive disorders, sleep disorders, obesity and other CNS DISORDERS
CA2588867A1 (fr) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Derive substitue de pyridone

Also Published As

Publication number Publication date
HUE026549T2 (hu) 2016-06-28
CN101258138A (zh) 2008-09-03
WO2006117609A3 (fr) 2007-03-22
CA2606262C (fr) 2013-08-20
EP1717235A3 (fr) 2007-02-28
DK1874746T3 (en) 2016-02-15
MX2007013384A (es) 2008-01-21
CN101258138B (zh) 2013-06-12
CA2606262A1 (fr) 2006-11-09
NO20075624L (no) 2007-11-28
EP1717235A2 (fr) 2006-11-02
JP2008539218A (ja) 2008-11-13
SG162732A1 (en) 2010-07-29
WO2006117609A2 (fr) 2006-11-09
MA29399B1 (fr) 2008-04-01
BRPI0612957A2 (pt) 2010-12-07
KR101291575B1 (ko) 2013-08-08
PL1874746T3 (pl) 2016-06-30
KR20080005997A (ko) 2008-01-15
EA019594B1 (ru) 2014-04-30
AU2006242950A1 (en) 2006-11-09
PT1874746E (pt) 2016-03-22
US20090111808A1 (en) 2009-04-30
ES2563065T3 (es) 2016-03-10
EA200702363A1 (ru) 2008-04-28
AU2006242950B2 (en) 2013-01-10
SI1874746T1 (sl) 2016-03-31
EP1874746A2 (fr) 2008-01-09
US8076329B2 (en) 2011-12-13
BRPI0612957B8 (pt) 2021-05-25
JP5693814B2 (ja) 2015-04-01
NO340728B1 (no) 2017-06-06
BRPI0612957B1 (pt) 2020-10-27
EP1874746B1 (fr) 2015-11-18
NZ562873A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
TNSN07393A1 (fr) Nouveaux ligands du recepteur h3 de l'histamine et leurs applications therapeutiques
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA31832B1 (fr) Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
TR200504337T1 (tr) Imatinib mezilat'ın yeni polimorfları
MA27697A1 (fr) Derive de phenethanolamine utilise dans le traitement des maladies respiratoires
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MA27991A1 (fr) Derives d'aminoquinoline et leur utilisation comme ligands d'adenosine a3
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
MA37384B1 (fr) Nouveaux dérivés de thiénopyrimidine, leurs procédés de préparation et leurs utilisations thérapeutiques.
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
JP2018526419A5 (fr)
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
ATE503746T1 (de) Neue imidazolidinderivate
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
TNSN05238A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur
DE602004031410D1 (de) Inden derivate als pharmazeutika
MA33222B1 (fr) 5-alcynylpyridines
MA33254B1 (fr) Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione